Recipharm Advanced Bio is redefining how RNA vaccines and therapeutics are manufactured by transforming a screening initiative into a predictive process-design platform. Its refined T7 polymerase library now guides construct-specific enzyme selection that lowers dsRNA impurities, cuts capping reagent costs, and streamlines GMP implementation — advancing the next generation of scalable, data-driven RNA production.
Access the full article here:
Recipharm Advanced Bio Is Advancing RNA Therapeutics | Recipharm